These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 12493362)

  • 1. New perspectives on the overactive bladder: pharmacokinetics and bioavailability.
    Gupta S; Sathyan G; Mori T
    Urology; 2002 Nov; 60(5 Suppl 1):78-80; discussion 80-1. PubMed ID: 12493362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overactive bladder: improving the efficacy of anticholinergics by dose escalation.
    MacDiarmid SA
    Curr Urol Rep; 2003 Dec; 4(6):446-51. PubMed ID: 14622497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.
    Appell RA; Sand P; Dmochowski R; Anderson R; Zinner N; Lama D; Roach M; Miklos J; Saltzstein D; Boone T; Staskin DR; Albrecht D;
    Mayo Clin Proc; 2001 Apr; 76(4):358-63. PubMed ID: 11322350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxybutynin topical and transdermal formulations: an update.
    Staskin DR; Salvatore S
    Drugs Today (Barc); 2010 Jun; 46(6):417-25. PubMed ID: 20571610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder.
    Goldenberg MM
    Clin Ther; 1999 Apr; 21(4):634-42. PubMed ID: 10363730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in medical management of overactive bladder.
    Richelson E; Elliott DS
    Mayo Clin Proc; 2003 Jun; 78(6):681-3. PubMed ID: 12934775
    [No Abstract]   [Full Text] [Related]  

  • 7. Detrol LA and Diropan XL for overactive bladder.
    Med Lett Drugs Ther; 2001 Apr; 43(1101):28. PubMed ID: 11283473
    [No Abstract]   [Full Text] [Related]  

  • 8. Oxybutynin transdermal (Oxytrol) for overactive bladder.
    Med Lett Drugs Ther; 2003 May; 45(1156):38-9. PubMed ID: 12736598
    [No Abstract]   [Full Text] [Related]  

  • 9. Update on overactive bladder: pharmacologic approaches on the horizon.
    Rovner ES; Wein AJ
    Curr Urol Rep; 2003 Oct; 4(5):385-90. PubMed ID: 14499063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxybutynin extended-release: a review of its use in the management of overactive bladder.
    Siddiqui MA; Perry CM; Scott LJ
    Drugs; 2004; 64(8):885-912. PubMed ID: 15059046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical oxybutynin for treating incontinence resulting from an overactive detrusor.
    Lose G; Nørgaard JP
    BJU Int; 2001 Jun; 87(9):767-73. PubMed ID: 11412211
    [No Abstract]   [Full Text] [Related]  

  • 12. Tolterodine.
    Hills CJ; Winter SA; Balfour JA
    Drugs; 1998 Jun; 55(6):813-20; discussion 821-2. PubMed ID: 9617596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.
    Diokno AC; Appell RA; Sand PK; Dmochowski RR; Gburek BM; Klimberg IW; Kell SH;
    Mayo Clin Proc; 2003 Jun; 78(6):687-95. PubMed ID: 12934777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal oxybutynin: for overactive bladder.
    Bang LM; Easthope SE; Perry CM
    Drugs Aging; 2003; 20(11):857-64. PubMed ID: 12964892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. POEMS (patient-oriented evidence that matters) spark discussion.
    Weiss BD
    J Fam Pract; 2001 Oct; 50(10):901. PubMed ID: 11674898
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug development for pediatric neurogenic bladder dysfunction: dosing, endpoints, and study design.
    Momper JD; Karesh A; Green DJ; Hirsch M; Khurana M; Lee J; Kim MJ; Mulugeta Y; Sachs HC; Yao L; Burckart GJ
    J Clin Pharmacol; 2014 Nov; 54(11):1239-46. PubMed ID: 24922179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference.
    Dmochowski RR; Newman DK; Sand PK; Rudy DC; Caramelli KE; Thomas H; Hoel G
    Clin Drug Investig; 2011; 31(8):559-571. PubMed ID: 21721591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.
    Van Kerrebroeck P; Kreder K; Jonas U; Zinner N; Wein A;
    Urology; 2001 Mar; 57(3):414-21. PubMed ID: 11248608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan.
    D'Souza AO; Smith MJ; Miller LA; Doyle J; Ariely R
    J Manag Care Pharm; 2008 Apr; 14(3):291-301. PubMed ID: 18439051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacotherapy of the overactive bladder and advances in drug delivery.
    Cannon TW; Chancellor MB
    Clin Obstet Gynecol; 2002 Mar; 45(1):205-17. PubMed ID: 11862073
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.